STRATEC Biomedical Systems AG, Birkenfeld, Germany, Greiner Bio-One GmbH, Frickenhausen, Germany, and Maven Biotechnologies, Pasadena, CA, USA, have signed their first agreement regarding a joint development program. This joint development of system solutions is based on a state of the art label-free detection technology for the diagnostics and pharmaceutical industries. These systems will combine reliability of high quality results with greatly reduced costs for laboratories and the industry. This agreement marks a milestone in the development of each company as it will combine expertise and technologies of three market leading companies in a perfectly complementary market.

Based on their experience of developing and manufacturing high quality analyzer systems for almost 30 years STRATEC will automate Maven’s LFIRE(TM) label-free detection methods using Greiner’s disposable technology featuring high optical performance.

Greiner has a proven track record of developing and producing medical disposables combining high quality optical features with cost effectiveness.

Maven’s label-free technology allows low to high density multiplexing for real time kinetic or end-point analysis. This technology is expected to gain significant market shares in the worldwide research and immunoassay market. By obviating much of the costs and time-consuming steps associated with traditionally labeled immunodiagnostics, and incorporating simultaneous analysis of multiple biomarkers, LFIRE(TM) can provide a truly cost effective enabling technology to meet the demands of personalized medicine.

Each party will be entitled to use the new technology for future developments and customer solutions.

About Greiner Bio-One GmbH – BioScience Division

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory equipment. The company is technology partner for universities, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well. With the BioScience division, Greiner Bio-One ranks among the leading providers of specialised products for the cultivation and analysis of cell and tissue cultures, as well as microplates for high-throughput screening, allowing industry and research most rapid and efficient drug screening. Additionally Greiner Bio-One develops innovative biochip technologies for genotyping. The German headquarters of the BioScience division in Frickenhausen (Baden-Württemberg) controls the whole research and development activities in the product ranges Cell Culture, High-Throughput Screening, Biochips and OEM.

Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 241.7 million Euro. It has over 1,200 employees and operates globally with 18 own subsidiaries and numerous distributors in more than 100 countries.

About Maven Biotechnologies

Maven Biotechnologies, LLC is a privately held biotechnology company located in Pasadena, CA, USA. It has developed the LFIRE(TM), a flexible, cost effective, label-free, high density imaging system for quantitative biomarker analysis that can characterize molecular binding reactions in real-time. The platform has practical advantages over existing products with applications in biomedical research, drug discovery, diagnostics, biodefense, biological manufacturing, biochip quality control production and other high growth fields. Maven’s technology has great promise to become a dominant technology platform for the new era of personalized medicine. With secure intellectual property including a number of issued patents and multiple pending patents, Maven is executing a multifaceted development strategy.

About STRATEC

STRATEC Biomedical Systems AG (https://www.stratec-biomedical.de) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.